Intraocular pressure-lowering efficacy and ocular safety of Rho-kinase inhibitor in glaucoma: a meta-analysis and systematic review of prospective randomized trials
Authors:
- 7 September 2021
- journal article
- review article
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 260 (3) , 937-948
Abstract
Purpose To evaluate the intraocular pressure (IOP)-reducing efficacy and safety of Rho-kinase inhibitor (RKI). Methods Published studies in PubMed and EMBASE were searched on March 20, 2021. Study selection and data extraction were performed according to PRISMA. Meta-analysis of the IOP-lowering effect was performed with the bivariate random-effects model, with studies categorized into 2 classes: RKI versus placebo and RKI versus another medication. The main outcome was the difference in IOP reduction between RKI and non-RKI groups. Subgroup analysis of adjunctive RKI efficacy and additional review of its major ocular adverse events (AE) were also performed. Results Ten (2.6%) out of 391 studies were retrieved. In the RKI versus placebo class, RKI showed greater IOP reduction after 4–8 weeks (mean difference = − 1.69 mmHg [− 2.22, − 1.16], P < 0.001). In the RKI versus another medication class, IOP reduction by RKI was noninferior to timolol 0.5% twice-daily after 4–8 weeks (mean difference = 0.39 mmHg [0.01, 0.76], P = 0.043) and 12 weeks (mean difference = 0.48 mmHg [0.11, 0.85]; P = 0.011). In the subgroup analysis, the mean difference in IOP reduction by adjunctive RKI and placebo was − 1.42 mmHg (P < 0.001). The most common ocular AE of RKI was conjunctival hyperemia (19–65%), followed by conjunctival hemorrhage (6–20%) and cornea verticillata (13–26%). Conclusions With a treatment duration of 1–3 months, RKI showed effective IOP reduction noninferior to timolol as monotherapy and as adjunctive therapy. Our results suggested RKI be a reliable IOP control medication; however, its higher incidence of some ocular complications should be attended to.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (MOST 107-2221-E-002-151)
- National Taiwan University Hospital Yunlin Branch (106.A001)
This publication has 46 references indexed in Scilit:
- Ocular Surface Disease Exacerbated GlaucomaJournal of Glaucoma, 2014
- How Ocular Surface Disease Impacts the Glaucoma Treatment OutcomeBioMed Research International, 2013
- Phase 2 Randomized Clinical Study of a Rho Kinase Inhibitor, K-115, in Primary Open-Angle Glaucoma and Ocular HypertensionAmerican Journal of Ophthalmology, 2013
- Emerging drugs for ocular hypertensionExpert Opinion on Emerging Drugs, 2010
- Meta-analysis of the Efficacy and Safety of α2-Adrenergic Agonists, β-Adrenergic Antagonists, and Topical Carbonic Anhydrase Inhibitors With Prostaglandin AnalogsArchives of Ophthalmology (1950), 2010
- Mechanistic basis of Rho GTPase-induced extracellular matrix synthesis in trabecular meshwork cellsAmerican Journal of Physiology-Cell Physiology, 2010
- Prevalence of Ocular Surface Disease in Glaucoma PatientsJournal of Glaucoma, 2008
- Rho-associated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contraction and motility in cultured human trabecular meshwork cellsExperimental Eye Research, 2006
- Conjunctival Hyperemia and the Use of Topical Prostaglandins in Glaucoma and Ocular HypertensionJournal of Ocular Pharmacology and Therapeutics, 2003
- Antiglaucoma medications: A review of safety and tolerability issues related to their useClinical Therapeutics, 2000